A GW Pharmaceuticals cannabis patent application (2019/0160023) for the use of the cannabinoid cannabidivarin (CBDV) in the treatment of Autism, Schizophrenia, and related psychological disorders was published this month. Under GW Pharma’s Pharmaceutical Pipeline development, CBDV has entered into phase 2 of clinical trials. Once through phase 3, GW Pharma can submit an application to the FDA presenting their evidence to seek FDA approval of the purified CBDV drug, just as was done for their purified CBD drug Epidiolex.